<DOC>
	<DOCNO>NCT01177098</DOCNO>
	<brief_summary>This study evaluate safety efficacy bimatoprost/timolol formulation A ophthalmic solution GanfortÂ® ( bimatoprost 0.03 % /timolol 0.5 % ophthalmic solution ) daily 12 week patient glaucoma ocular hypertension .</brief_summary>
	<brief_title>Safety Efficacy New Formulation Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution Patients With Glaucoma Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Patient ocular hypertension glaucoma eye Requires IOPlowering therapy eye Active recurrent eye disease would interfere interpretation study data either eye History eye surgery laser either eye within 6 month Required chronic use eye medication study Anticipated wear contact lens study . Intermittent use oral , intramuscular , intravenous corticosteroid within 21 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>